/

Sociétés

La

Non vérifié

Lantern Pharma

Ce que nous écrivons

BiotechnologieÉvénementsIndustrieIndustrie pharmaceutiqueOncologie

3 communiqués de presse

Voir tous les communiqués de presse

07/08/2024

Oncologie

Santé

Médecine - Divers

Santé Publique

Industrie pharmaceutique

Biotechnologie

Événements

Industrie

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Source

Émetteur

1.00

0

05/08/2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Source

Émetteur

1.00

0

10/07/2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0